Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-23
2011-08-23
Gupta, Anish (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S345000, C514S277000, C514S183000, C546S300000, C546S290000, C424S486000
Reexamination Certificate
active
08003672
ABSTRACT:
Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabiniod inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.
REFERENCES:
patent: 6699871 (2004-03-01), Edmondson et al.
patent: 7326708 (2008-02-01), Cypes et al.
patent: 2005/0008706 (2005-01-01), Holm et al.
patent: 2007/0104741 (2007-05-01), Murty et al.
patent: WO03/077847 (2003-09-01), None
patent: WO03/077847 (2003-09-01), None
patent: WO2006/119260 (2006-11-01), None
patent: WO2006/119260 (2006-11-01), None
STN Registry record for taranabant (Jul. 2004).
“The mechanisms of drug release from solid dispersions in water-soluble polymers” by Craig, Int. J. Pharmaceut. 231, 131-44 (2002).
“Solid Dispersion of Poorly Water-Soluble Drugs: Early Promises, Subsequent Problems, and Recent Breakthroughs” by Serajuddin, J. Pharm. Sci. 88, 1058-66 (1999).
“Drug delivery strategies for poorly water-soluble drugs” by Fahr et al., Expert Opin. Drug Deliv. 4, 403-16 (2007).
“Improving drug solubility for oral delivery using solid dispersions” by Leuner et al., Eur. J. Pharmaceut. Biopharm. 50, 47-60 (2000).
“Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs” by Vasconcelos et al., Drug Discovery Today 12, 1068-75 (2007).
Geers Sarah
McKelvey Craig
Moser Justin
Rege Bhagwant
Sotthivirat Sutthilug
Fair Janet E.
Gupta Anish
Merck Sharp & Dohme Corp.
Todaro John C.
West Theodore R
LandOfFree
CB-1 receptor modulator formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CB-1 receptor modulator formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CB-1 receptor modulator formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2722543